Oliner K, Shiller M, Schmid P, Ratcliffe M, Schetter A, Tsao M
Clin Cancer Res. 2024; 31(5):795-800.
PMID: 39724199
PMC: 11873800.
DOI: 10.1158/1078-0432.CCR-24-2729.
Leven A, Wagner N, Nienaber S, Messiha D, Tasdogan A, Ugurel S
Basic Res Cardiol. 2024; 120(1):133-152.
PMID: 39658699
PMC: 11790718.
DOI: 10.1007/s00395-024-01092-8.
Oo N, Weadick C, Murphy L, OReilly S
BJC Rep. 2024; 2(1):49.
PMID: 39516678
PMC: 11524057.
DOI: 10.1038/s44276-024-00074-6.
Iliodromitis K, Hoiczyk M, Bimpong-Buta N, Seyfarth M, Bogossian H
Herzschrittmacherther Elektrophysiol. 2024; 35(3):177-182.
PMID: 39129002
DOI: 10.1007/s00399-024-01033-x.
Chamorey E, Gal J, Mograbi B, Milano G
Pharmaceuticals (Basel). 2024; 17(7).
PMID: 39065667
PMC: 11279680.
DOI: 10.3390/ph17070816.
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.
Wermke M, Holderried T, Luke J, Morris V, Alsdorf W, Wetzko K
J Immunother Cancer. 2024; 12(7).
PMID: 39038917
PMC: 11268062.
DOI: 10.1136/jitc-2023-008668.
A method for predicting drugs that can boost the efficacy of immune checkpoint blockade.
Xia Y, Li X, Bie N, Pan W, Miao Y, Yang M
Nat Immunol. 2024; 25(4):659-670.
PMID: 38499799
DOI: 10.1038/s41590-024-01789-x.
Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach.
Murtagh G, deFilippi C, Zhao Q, Barac A
Front Cardiovasc Med. 2024; 11:1350585.
PMID: 38410245
PMC: 10894940.
DOI: 10.3389/fcvm.2024.1350585.
Artificial Intelligence and Anticancer Drug Development-Keep a Cool Head.
Bailleux C, Gal J, Chamorey E, Mograbi B, Milano G
Pharmaceutics. 2024; 16(2).
PMID: 38399265
PMC: 10893490.
DOI: 10.3390/pharmaceutics16020211.
Disproportional inflation of clinical trial costs: why we should care, and what we should do about it.
Hijma H, Zhuparris A, van Hoogdalem E, Cohen A
Nat Rev Drug Discov. 2024; 23(2):85-86.
PMID: 38195708
DOI: 10.1038/d41573-024-00002-w.
Neoantigen cancer vaccines: a new star on the horizon.
Li X, You J, Hong L, Liu W, Guo P, Hao X
Cancer Biol Med. 2024; 21(4).
PMID: 38164734
PMC: 11033713.
DOI: 10.20892/j.issn.2095-3941.2023.0395.
The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With Atezolizumab.
Smith K, Pritzl S, Yu W, Bara I, Thanarajasingam G, Kaul M
JTO Clin Res Rep. 2024; 4(12):100611.
PMID: 38162172
PMC: 10755354.
DOI: 10.1016/j.jtocrr.2023.100611.
ICBcomb: a comprehensive expression database for immune checkpoint blockade combination therapy.
Xia Y, Gao Y, Liu M, Li L, Pan W, Mao L
Brief Bioinform. 2023; 25(1).
PMID: 38095856
PMC: 10753530.
DOI: 10.1093/bib/bbad457.
National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval.
Cliff E, Rome R, Kesselheim A, Rome B
JAMA Netw Open. 2023; 6(11):e2343285.
PMID: 37962889
PMC: 10646727.
DOI: 10.1001/jamanetworkopen.2023.43285.
[Side effects of immune checkpoint inhibitor therapy : What intensive care specialists need to know].
Buchtele N, Knaus H, Schellongowski P
Med Klin Intensivmed Notfmed. 2023; 119(2):85-96.
PMID: 37661230
PMC: 10901948.
DOI: 10.1007/s00063-023-01057-0.
Toxicity, disease management and outcome of treatment with immune checkpoint inhibitors by sex in patients with cancer and preexisting autoimmune disease.
Liu M, Christ L, Richters A, Ozdemir B
Oncol Lett. 2023; 26(3):377.
PMID: 37559593
PMC: 10407854.
DOI: 10.3892/ol.2023.13963.
Trends in the approval of cancer therapies by the FDA in the twenty-first century.
Scott E, Baines A, Gong Y, Moore Jr R, Pamuk G, Saber H
Nat Rev Drug Discov. 2023; 22(8):625-640.
PMID: 37344568
DOI: 10.1038/s41573-023-00723-4.
Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy.
Chen Y, Dong H, Wei Y, Yang Y, Ming J, Yu H
BMJ. 2023; 381:e069963.
PMID: 37321628
PMC: 10266439.
DOI: 10.1136/bmj-2022-069963.
Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors.
Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Yepez Guevara E
Am J Gastroenterol. 2023; 118(9):1609-1617.
PMID: 37307533
PMC: 11809494.
DOI: 10.14309/ajg.0000000000002361.
Vinorelbine and Intermittent Cyclophosphamide Sensitize an Aggressive Myc-Driven B-Cell Lymphoma to Anti-PD-1 by an Immunological Memory Effective against Tumor Re-Challenge.
Orecchioni S, Falvo P, Talarico G, Mitola G, Bravetti G, Mancuso P
J Clin Med. 2023; 12(7).
PMID: 37048617
PMC: 10095342.
DOI: 10.3390/jcm12072535.
